Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM
Krzysztof Kałwak(Poznan University of Medical Sciences), Franco Locatelli(Bambino Gesù Children's Hospital), Jean‐Hugues Dalle(Inserm), Christina Peters(Cancer Research Institute of the Slovak Academy of Sciences), Jerry Stein(Schneider Children's Medical Center), Ulrike Pötschger(St Anna Children's Hospital), Peter Bader(Goethe University Frankfurt), Gergely Kriván(National Center for Epidemiology), Ernest Bilić(University Hospital Centre Zagreb), Katharina Kleinschmidt(University Hospital Regensburg), Jochen Buechner(Oslo University Hospital), Melissa Gabriel(University of Southern California), M. Akif Yeşilipek(Akdeniz University), Roland Meisel(Düsseldorf University Hospital), Cristina Díaz de Heredia(Universitat Autònoma de Barcelona), Jacek Toporski(Skåne University Hospital), Evgenios Goussetis(Boston Children's Hospital), Marianne Ifversen(Copenhagen University Hospital), Raquel Staciuk, Adriana Balduzzi(Azienda Ospedaliera San Gerardo), Marc Ansari(University of Geneva), Kim Vettenranta(Universität Hamburg), Marc Bierings(University Medical Center Utrecht), Laura M. Moser(Goethe University Frankfurt), Peter Švec(Comenius University Bratislava), Petr Sedláček(University Hospital in Motol), Marleen Renard, Tayfun Güngör, Herbert Pichler(St Anna Children's Hospital)
Cited by 3
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase–mediated tryptophan degradation
|Blood|2004|1.6k
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|738
B cell–helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen
|Nature Immunology|2011|724
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724